Latest news with #NationalAccountsStatistics2024
Time of India
3 days ago
- Business
- Time of India
India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report
Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities. The report added that the pharma sector firms studied by it may witness a 11 per cent year-on-year (YoY) sales growth, driven by an 11 per cent YoY increase in the India business along with 2 per cent QoQ growth in US sales (+2 per cent YoY). The EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a financial metric used to assess a company's profitability and operational efficiency. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 이 게임은 대부분의 TV 프로그램보다 더 재미있어요 – 게다가 무료예요. Raid: Shadow Legends 플레이하기 Undo The report stated that EBITDA margins for the pharma segment are expected to decrease by 42bps YoY, driven by price erosion in the US and an expected increase in research and development (R&D). The hospital business is projected to grow by 15 per cent YoY, as muted occupancy will be partly supported by steady ARPOB, or Average Revenue Per Occupied Bed, which is a key performance indicator used in the healthcare industry to assess a hospital's financial performance. Live Events India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion, with domestic consumption valued at USD 23.5 billion and exports valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third-largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry, i.e., Pharmaceuticals, medicinal and botanical products, is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is Rs 1,75,583 crores.
India Gazette
3 days ago
- Business
- India Gazette
India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report
New Delhi [India], July 12 (ANI): Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities. The report added that the pharma sector firms studied by it may witness a 11 per cent year-on-year (YoY) sales growth, driven by an 11 per cent YoY increase in the India business along with 2 per cent QoQ growth in US sales (+2 per cent YoY). The EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a financial metric used to assess a company's profitability and operational efficiency. The report stated that EBITDA margins for the pharma segment are expected to decrease by 42bps YoY, driven by price erosion in the US and an expected increase in research and development (R&D). The hospital business is projected to grow by 15 per cent YoY, as muted occupancy will be partly supported by steady ARPOB, or Average Revenue Per Occupied Bed, which is a key performance indicator used in the healthcare industry to assess a hospital's financial performance. India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion, with domestic consumption valued at USD 23.5 billion and exports valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third-largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry, i.e., Pharmaceuticals, medicinal and botanical products, is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is Rs 1,75,583 crores. (ANI)
Hans India
06-07-2025
- Business
- Hans India
Pharma sector set for 11% YoY growth in Q1FY26 driven by global momentum: Report
Pharmaceutical companies in India are projected to deliver an 11% year-on-year (YoY) growth in both sales and EBITDA for the first quarter of FY26, according to a recent report by Kotak Institutional Equities. The growth is expected to be driven by sustained momentum across key international markets, despite slightly muted domestic demand in April and March. The hospital segment is also expected to shine with a robust 17% YoY increase in sales and EBITDA, attributed to increased patient footfalls, capacity expansions through new bed additions, and a modest improvement in Average Revenue Per Occupied Bed (ARPOB). Diagnostics players are forecast to see a 14% growth in sales, fueled by higher volumes, an improved service mix, and mergers and acquisitions activity. The Indian pharmaceutical market was valued at USD 50 billion in FY24, with domestic consumption contributing USD 23.5 billion and exports accounting for USD 26.5 billion. India continues to hold its place as the world's third-largest pharmaceutical producer by volume and 14th by value. The industry's portfolio spans generic and bulk drugs, OTC products, vaccines, biosimilars, and biologics. As per the National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, the pharmaceutical sector's total output stood at ₹4.56 lakh crore for FY23 at constant prices, with ₹1.75 lakh crore as value added. With over 9.25 lakh people employed in the sector during FY23, the Indian government has been actively promoting pharmaceutical innovation. The Department of Pharmaceuticals has set up seven National Institutes of Pharmaceutical Education and Research (NIPERs) to foster advanced research and academic excellence. To accelerate innovation, the department has also rolled out the National Policy on R&D and Innovation in the Pharma-MedTech Sector, aimed at nurturing an entrepreneurial ecosystem and positioning India as a global leader in drug discovery and medical device development.
Mint
06-07-2025
- Business
- Mint
Pharma firms likely to post 11% growth in sales, EBITDA in Q1FY26: Report
New Delhi [India], July 6 (ANI): Pharmaceutical firms are expected to post 11 per cent year-on-year growth in both sales and EBITDA for the first quarter of Financial Year 2026 (Q1FY26), driven by sustained momentum across most markets, according to a report by Kotak Institutional Equities. However, the report added that the muted domestic demand in April and March may slightly offset gains. The hospitals segment is projected to see robust 17 per cent year-on-year growth in both sales and EBITDA, supported by increased footfalls, new bed additions, and a modest rise in ARPOB. In diagnostics, volume growth, better mix, and M&A activity are expected to contribute to a 14 per cent YoY sales increase across the coverage. "For pharma companies, we expect continued traction across most markets to drive 11%/11% yoy growth in overall sales/EBITDA in 1QFY26," the report added. India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion with domestic consumption valued at USD 23.5 billion and export valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry i.e. Pharmaceuticals, medicinal and botanical products is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is ₹ 1,75,583 crores. As per government data 9,25,811 number of persons are engaged in Pharmaceuticals, medicinal and botanical products industry during FY 2022-23. Research & Development (R&D) and innovation in Pharma Sector is done by number of institutions and organizations under various scientific Ministries/Departments. The Department of Pharmaceuticals has set up seven National Institutes of Pharmaceutical Education & Research (NIPERs) as institutes of national importance, which besides imparting postgraduate and doctorate education, conduct high end research in various pharma specializations. Further, Department has framed a "National Policy on Research & Development and Innovation in Pharma-MedTech Sector in India" to encourage R&D in pharmaceuticals and medical devices.
Mint
06-07-2025
- Business
- Mint
Pharma firms likely to post 11% growth in sales, EBITDA in Q1FY26: Report
New Delhi [India], July 6 (ANI): Pharmaceutical firms are expected to post 11 per cent year-on-year growth in both sales and EBITDA for the first quarter of Financial Year 2026 (Q1FY26), driven by sustained momentum across most markets, according to a report by Kotak Institutional Equities. However, the report added that the muted domestic demand in April and March may slightly offset gains. The hospitals segment is projected to see robust 17 per cent year-on-year growth in both sales and EBITDA, supported by increased footfalls, new bed additions, and a modest rise in ARPOB. In diagnostics, volume growth, better mix, and M&A activity are expected to contribute to a 14 per cent YoY sales increase across the coverage. "For pharma companies, we expect continued traction across most markets to drive 11%/11% yoy growth in overall sales/EBITDA in 1QFY26," the report added. India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion with domestic consumption valued at USD 23.5 billion and export valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry i.e. Pharmaceuticals, medicinal and botanical products is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is ₹ 1,75,583 crores. As per government data 9,25,811 number of persons are engaged in Pharmaceuticals, medicinal and botanical products industry during FY 2022-23. Research & Development (R&D) and innovation in Pharma Sector is done by number of institutions and organizations under various scientific Ministries/Departments. The Department of Pharmaceuticals has set up seven National Institutes of Pharmaceutical Education & Research (NIPERs) as institutes of national importance, which besides imparting postgraduate and doctorate education, conduct high end research in various pharma specializations. Further, Department has framed a "National Policy on Research & Development and Innovation in Pharma-MedTech Sector in India" to encourage R&D in pharmaceuticals and medical devices. The policy also creates an ecosystem for innovation in the sector in order for India to become leader in drug discovery and innovative medical devices through incubating an entrepreneurial environment to build a robust ecosystem to ensure the holistic development of R&D and Innovation. (ANI)
